BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 18, 2026
Home » Newsletters » BioWorld Asia

BioWorld Asia

Aug. 6, 2014

View Archived Issues

Disappointing news on PI-88 casts shadow over biotech in Taiwan

TAIPEI, Taiwan – Medigen Biotechnology Corp. said following a meeting Sunday with an independent committee to discuss results midway through the multinational phase III trial for PI-88, the company's adjuvant treatment of hepatocellular carcinoma after surgical resection, preliminary results showed no improvement of survival rates over placebo. The company's stock price has been hit hard in response, as have many other companies in Taiwan's drug development sector. Read More

Jinghua is eyeing biotech market with Kingsley stake

HONG KONG – A small Chinese biopharmaceutical company expects that the support and resources of a traditional Chinese medicine (TCM) and active pharmaceutical ingredients manufacturer will help it develop a stronger biologics pipeline. Read More

Trial date in China set for investigators in GSK bribery scandal

HONG KONG – The Shanghai No.1 Intermediate People's Court announced Monday the date for the trial of the two investigators allegedly linked to Glaxosmithkline plc's (GSK) bribery scandal in China. Read More

WHO proposes middle ground for biosimilar naming scheme

It's not set in stone yet, but the World Health Organization (WHO) is proposing a voluntary, global naming scheme for biologics, both novel and biosimilar. Read More

18-month-old Mabspace aims to fast-track FOBs in China for cancer, CKD

SHANGHAI – For Xueming Qian, CEO and founder of Mabspace Co. Ltd., an antibody discovery engine based in Suzhou, the writing was on the wall. While pharma was de-emphasizing early stage research and putting it into the hands of biotechs in the U.S., the economy in China had hit an inflection point, the momentum was building. China was the place to be. Read More

Other news to note

Reprocell Inc., of Yokohama, Japan, a venture company established by the University of Tokyo and Kyoto University that offers commercial induced pluripotent stem (iPS) cells, acquired Reinnervate Ltd., of County Durham, UK, and Bioserve Biotechnologies Ltd., of Beltsville, Md., to accelerate its iPS cell business by establishing a global distribution network and developing patient-derived iPS cells in areas such as Alzheimer's, Parkinson's and cardiovascular diseases. Read More

Appointments and advancements

Astellas Pharma US Inc., of Northbrook, Ill., part of Astellas Pharma Inc., of Tokyo, appointed Moyra Knight as the head of corporate and employee communications in the Americas region. Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing